The effects of an irreversible dopamine receptor antagonist, N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), on the regulation of muscle tone in the rat: the role of the substantia nigra

1998 ◽  
Vol 251 (2) ◽  
pp. 77-80 ◽  
Author(s):  
Kim M Hemsley ◽  
Ann D Crocker
2017 ◽  
Vol 7 ◽  
pp. e954
Author(s):  
Afshin Roostaei ◽  
Gholamhassan Vaezi ◽  
Mohammad Nasehi ◽  
Ali Haeri-Rohani ◽  
Mohammad-Reza Zarrindast

Background: Diabetes is one of the most common endocrine diseases characterized by hyperglycemia. It is caused by an absolute or relative insulin deficiency or an insulin function deficiency. It is one of the major risk factors of depression, with the rate of depression in diabetic patients amounting to as high as 30%. This study examined the role of dopamine receptors in streptozotocin (STZ)-induced depressive-like behavior using the forced swim test (FST). Materials and Methods: This study was performed on 56 Wistar male rats. STZ at doses of 30 and 60 mg/kg body weight was administered via intraperitoneal (IP) route to induce diabetes and depression in rats. Thereafter, by using halobenzazepine (SCH23390) (D1 dopamine receptor antagonist) and sulpiride (D2 receptor dopamine receptor antagonist), the role of dopamine receptors in STZ-induced depression was studied. The one-way analysis of variance technique, Tukey’s range test, and t-test were used to analyze the data. The P-value less than 0.05 was regarded as statistically significant. Results: Our study showed that STZ at doses of 30 and 60 mg/kg, two weeks after injection, caused prolonged immobility in FST, indicating depressive-like behavior (P<0.05 and P<0.01, respectively). SCH23390 (0.001 mg/mL/kg) and sulpiride (0.1mg/mL/kg) did not change the variables of depression in animals that received STZ (at doses of 30 and 60 mg/mL/kg) two weeks before (P>0.05). Conclusion: According to our study, STZ has a depressive-like behavior two weeks after injection, and dopamine receptors do not play a role in depression associated with STZ use. [GMJ.2018;7:e954]


1987 ◽  
Vol 7 (11) ◽  
pp. 839-842 ◽  
Author(s):  
Abdulrahim Abu-Jayyab ◽  
Ahmed Mahgoub

The dopamine receptor agonist, bromocriptine, in a dose of 10 mg/kg i.p. for 14 days, in rats caused a significant increase in liver Na+/K+-ATPase activity, whereas sulpiride, a dopamine receptor antagonist, in a dose of 10 mg/kg, i.p. for 14 days, in rats, caused a significant decrease in liver Na+/K+-ATPase activity. Injection of bromocriptine and sulpiride simultaneously in a group of rats, under the same conditions and using the same doses caused a complete block of both stimulatory activity of bromocriptine and inhibitory activity of sulpiride on liver Na+/K+-ATPase activity. It is suggested that Na+/K+-ATPase may have a role in the action of dopaminergic-D2 receptors.


Luminescence ◽  
2015 ◽  
Vol 31 (1) ◽  
pp. 63-66 ◽  
Author(s):  
Mohamed Hefnawy ◽  
Mostafa Mohamed ◽  
Mohamed Abunassif ◽  
Amer Alanazi ◽  
Abdulrahman Al-Majed ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document